Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Effect of GB001 in Patients With Chronic Rhinosinusitis With or Without Nasal Polyps

Next Previous
Trial Profile

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Effect of GB001 in Patients With Chronic Rhinosinusitis With or Without Nasal Polyps

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GB 001 (Primary)
  • Indications Rhinosinusitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms TITAN
  • Sponsors Gossamer Bio

Most Recent Events

  • 13 Oct 2020 According to a Gossamer Bio media release, the company will host a conference call and live audio webcast to discuss the results from this trial.
  • 13 Oct 2020 According to a Gossamer Bio media release, the company do not plan to continue further development of GB001 in chronic rhinosinusitis.
  • 13 Oct 2020 Primary endpoint (Sino-Nasal Outcome Test-22 (SNOT-22)) has not been met, according to a Gossamer Bio media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top